Novo Nordisk To Target 'New GLP-1 Patients Only' With Weekly Ozempic
Novo Nordisk's head of international operations says trying to switch diabetes patients over to newly approved Ozempic from other GLP-1 medicines is not part of its commercial strategy.
You may also be interested in...
Smarting from a disappointing advisory committee review for baricitinib, Lilly pointed to the strong first quarter performance of its drugs launched since 2014, especially Trulicity.
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
Seven products containing a new active substance were approved in Europe in the first two months of 2018: Shire's Adynovi and Roche/Chugai's Hemlibra for hemophilia A, Roche's Ocrevus for multiple sclerosis, Kyowa Kirin's Crysvita for hypophosphatemia, AstraZeneca's Fasenra for asthma, Novo Nordisk's Ozempic for diabetes, and MSD's Prevymis for prophylaxis of cytomegalovirus infection.